Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem. Ublituximab is a novel, glycoengineered anti‐CD20 monoclonal antibody with single‐agent activity in relapsed CLL. We report the results of a phase 2 study evaluating combinat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Sharman, Jeff P., Farber, Charles M., Mahadevan, Daruka, Schreeder, Marshall T., Brooks, Heather D., Kolibaba, Kathryn S., Fanning, Suzanne, Klein, Leonard, Greenwald, Daniel R., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Burke, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299538/
https://ncbi.nlm.nih.gov/pubmed/27982425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14447
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados